Abstract:Background: Transcatheter arterial chemoembolization (TACE) combined with ablation has been widely used for treating unresectable hepatocellular carcinoma (HCC). However, the technique with which TACE should be combined for it to be more effective remains unknown.Purpose: To retrospectively evaluate the efficacy and safety of TACE combined with microwave ablation (MWA) vs. TACE combined with cryoablation (CRA) in treating unresectable HCC.Materials and Methods: From January 2011 to December 2018, 108 patients diagnosed with unresectable HCC were divided into either the TACE-MWA group (n = 48) or TACE-CRA group (n = 60). Overall survival (OS) and time to progression (TTP) were compared between the two groups. To reduce potential bias, a propensity score matching (PSM) was performed. Complications were observed. Kaplan-Meier survival curves were constructed and compared using the log-rank test.Results : The baseline characteristics of the two groups were balanced. The median OS was 20.9 months (95% CI 14.3–27.6 months) in the TACE-MWA group and 13.0 months (95% CI 8.8–17.1 months) in the TACE-CRA group (P = 0.096). The median TTP was 8.8 months (95% CI 4.3–13.4 months) in the TACE-MWA group and 9.3 months (95% CI 7.1–11.5 months) in the TACE-CRA group (P = 0.675). After PSM, 48 patients remained in each group. The median OS in the TACE-MWA and TACE-CRA groups was 20.9 months (95% CI 14.3–27.6 months), and 13.5 months (95% CI 8.4–18.6 months, P = 0.100), respectively. The median TTP in the TACE-MWA and TACE-CRA groups was 8.8 months (95% CI 4.3–13.4 months), and 8.6 months (95% CI 3.1–14.2 months, P = 0.909), respectively. The overall incidence rate of ablation-related complications was lower in the TACE-MWA group than in the TACE-CRA group (66.7 vs. 88.3%, P = 0.006). Multivariate analysis showed that the presence of portal vein tumor thrombus (PVTT) and the maximum diameter of intrahepatic tumor were significant prognostic factors for OS and TTP.Conclusion: The efficacy of TACE-MWA and TACE-CRA in the treatment of unresectable HCC was comparable. TACE-MWA was more promising because of a lower complication rate, especially with regard to thrombocytopenia. Further prospective randomized controlled trials are required to validate our findings.

Clinical Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with ;radiofrequency Ablation for Hepatocellular Carcinoma under Liver Capsular

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Combination of transcatheter arterial chemoembolization and radiofrequency ablation in hepatocellular carcinoma treatment

[On the relations between biotin and creatine synthesis in vivo and in vitro].

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Treating of Hepatic Metastases

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients

Comparison of the Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Versus Monotherapy in Patients with Liver Cancer

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Delays Tumor Progression and Prolongs Overall Survival in Patients with Intermediate (BCLC B) Hepatocellular Carcinoma.

Elimination Rate Of Tumor'S Blood Supply, Tumor Necrosis Rate And Adverse Reactions In Advanced Hepatocellular Carcinoma Treated By Transcatheter Arterial Chemoembolization With Radiofrequency Ablation

Percutaneous Thermal Ablation Combined with Simultaneous Transarterial Chemoembolization for Hepatocellular Carcinoma ≤5 Cm

Non-cardiac surgery and volatile agents – Back to the future

TACE-assisted multi-image guided radiofrequency ablation for the treatment of single hepatocellular carcinoma ≤ 5 cm: a retrospective study

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Malignancy at High-risk ;Locations

Randomized Clinical Trial of Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Intermediate Stage (BCLC Stage B) Hepatocellular Carcinoma Beyond Milan Criteria.

Radiofrequency Ablation Following First-Line Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria

Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma.

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

Sequential Transcatheter Arterial Chemoembolization, Three-Dimensional Conformal Radiotherapy, and High-Intensity Focused Ultrasound Treatment for Unresectable Hepatocellular Carcinoma Patients

Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation

Changes in Immunological Function after Treatment with Transarterial Chemoembolization Plus Radiofrequency Ablation in Hepatocellular Carcinoma Patients